Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 107 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Amnesia-Memory Loss Clear all

Conditions: Early Memory Loss, Mild Cognitive Impairment, Alzheimer's Disease, Vascular Dementia
Interventions: CerefolinNAC®; Other
Lead sponsor: Pamlab, Inc.; Industry
Eligibility: 50 Years to 80 Years
Enrollment: 204 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Hickory, North Carolina

Conditions: Mild Cognitive Impairment, Alzheimer Disease, Cognitive Impairment, Cognitive Decline, Memory Loss, Memory Impairment
Interventions: Moderate Intensity Continuous Training (MICT), Chair-based Stretch, High-Intensity Interval Training (HIIT), Combined Aerobic Resistance Exercise (CARE); Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 65 Years and older
Enrollment: 216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Falls (Accidents) in Old Age
Interventions: FallsTalk-C, FallsTalk; Behavioral
Lead sponsor: Brookside Research & Development Company; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Freeland, Washington

Conditions: Memory Loss, Alzheimer Disease, Dementia
Interventions: PorchLight; Other
Lead sponsor: University of Minnesota; Other
Eligibility: Not listed
Enrollment: 342 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Alzheimer Disease
Interventions: ADRD Care Delivery Protocol; Other
Lead sponsor: VA Pittsburgh Healthcare System; Federal
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Alzheimer Disease, Early Onset, Alzheimer Disease, Alzheimer Dementia, Mild Cognitive Impairment, Memory Disorders, Memory Loss, Memory Impairment, Memory Disorders, Age Related, Alzheimer Disease, Late Onset, Cognitive Impairment, Dementia, Mild, Dementia, Alzheimer Type, Cognitive Decline
Interventions: GammaSense Stimulation System (non-invasive, non-significant risk); Device
Lead sponsor: Cognito Therapeutics, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Newton, Massachusetts

Conditions: Mild Cognitive Impairment, Memory Disorders, Memory Loss
Interventions: HD-tDCS combined with CT, sham HD-tDCS combined with CT; Device
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 50 Years to 90 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Dementia
Interventions: 3D-RT, RT-Verbal; Behavioral
Lead sponsor: Moai Technologies LLC; Other
Eligibility: Not listed
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 2
States / cities: St Louis, Missouri • Arlington, Texas

Conditions: Alzheimer Disease, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Memory Loss, Memory Disorders, Memory Impairment
Interventions: Biomarker Data Collection; Other
Lead sponsor: GAP Innovations, PBC; Industry
Eligibility: 60 Years to 85 Years
Enrollment: 1,002 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 16
States / cities: Aventura, Florida • Coral Gables, Florida • Lady Lake, Florida + 13 more

Conditions: Mild Cognitive Impairment, Alzheimer Disease
Interventions: Canakinumab, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 45 Years to 90 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Charlestown, Massachusetts • Stony Brook, New York

Conditions: Mild Cognitive Impairment
Interventions: Ketogenic diet, Healthy high carbohydrate diet; Other
Lead sponsor: University of Cincinnati; Other
Eligibility: 50 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Memory Loss Associated With Corticosteroid Use, Manic State Associated With Corticosteroid Use
Interventions: Levetiracetam, Keppra; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Alzheimer's Dementia
Interventions: Resonator; Device
Lead sponsor: pico-tesla Magnetic Therapies, LLC; Industry
Eligibility: 55 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Alzheimer's Disease
Interventions: donepezil; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 40 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Alzheimer Disease, Memory Disorders
Interventions: Estrogen, Estrogen and Progesterone; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 65 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: Ends 2007
U.S. locations: 22
States / cities: Birmingham, Alabama • Irvine, California • Stamford, Connecticut + 18 more

Conditions: Vascular Dementia
Interventions: Rivastigmine; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 708 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 17
States / cities: Irvine, California • San Francisco, California • Boynton Beach, Florida + 14 more

Conditions: Alzheimer Disease
Interventions: MAR; Drug
Lead sponsor: Noah Pharmaceuticals, Inc.; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 16
States / cities: Scottsdale, Arizona • Huntington Beach, California • DeLand, Florida + 11 more

Conditions: Memory Loss (Excluding Dementia), Healthy Lifestyle, Risk Reduction Behavior
Interventions: My Healthy Brain 1, My Healthy Brain 2; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Memory Loss, Alzheimer's Disease, Dementia
Interventions: Early Stage Memory Loss Support Group, Educational Seminar; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: Not listed
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Mild Cognitive Impairment, Alzheimer Disease
Interventions: lyophilized blueberry supplement; Dietary Supplement
Lead sponsor: Duke University; Other
Eligibility: 55 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Mild Cognitive Impairment, Alzheimer Disease, Memory Impairment
Interventions: CORT108297, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 55 Years and older
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Epilepsy, Seizures, Cognitive Impairment, Mild, Memory Disorders, Memory Loss
Interventions: Scopolamine (0.4mg), Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 55 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dementia of Alzheimer Type, Alzheimer Disease, Late Onset, Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Dementia
Interventions: Not listed
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 4,884 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2024
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Memory Loss, Memory Deficits, Dementia, Alzheimer Disease
Interventions: Memtrax Memory screening test; Behavioral
Lead sponsor: John Wesson Ashford Jr; Federal
Eligibility: 21 Years and older
Enrollment: 1 participant
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2023
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

NAC-003 P.L.U.S. Program (Progress Through Learning Understanding & Support)

A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses

FallsTalk Falls Prevention Program for Caregivers and Persons With Memory Loss or Dementia

The PorchLight Project

Improving Access to Care for Veterans With Memory Loss

Study of Tolerability, Safety and Efficacy of Sensory Stimulation at Multiple Dose Levels to Improve Brain Function (Etude Study)

A Study of HD-tDCS and Cognitive Training to Improve Cognitive Function in MCI

Creating Physical Objects With 3D Printers to Stimulate Reminiscing for Memory Loss [2 R44 AG049548-02A1]

A Biomarker Database to Investigate Blood-Based and Digital Biomarkers in Participants Screened for Alzheimer's Disease (Bio-Hermes)

Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease

Energy Metabolism and Cognitive Aging

Levetiracetam for Neuroprotection Against Corticosteroid-induced Hippocampal Dysfunction: A Proof of Concept Study

Safety and Efficacy Study of Magnetic Fields to Treat Alzheimer's Disease

Donepezil and Brain Activity Patterns in Those at Risk For Alzheimer's Disease

Alzheimer's Disease Prevention Trial

Efficacy and Safety of Rivastigmine Capsules in Patients With Probable Vascular Dementia

Phase 2 Estimation Study of Fixed Dose Drugs Combination Type of Polypill

Brain Health Program for Older Adults With Subjective Cognitive Decline

Efficacy of Early Stage Alzheimer's Support Groups

Effect of Blueberry Supplementation on Alzheimer's Biomarkers

Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X)

Pharmacological Modulation of Brain Oscillations in Memory Processing

Genetic Studies in Familial Dementia

Screening for Memory Studies